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1. Introduction 
Schizophrenia is a common severe psychiatric disorder which affects approximately 1% of 
the world population. Imaging studies and postmortem analysis have clearly shown that 
schizophrenia is not a mere functional disorder, but rather includes several histological 
abnormalities in various areas of the brain. Today, deficits in brain development or a 
malfunction in the dopaminergic system are considered the leading hallmarks of 
schizophrenia (Fatemi & Folsom, 2009; Howes & Kapur, 2009; Iritani, 2007).  
Although the pathogenesis of schizophrenia remains still unresolved, it is now clear that this 
disorder is the result of a complex interplay between inheritable genetic mutations in a large 
number of genes (a few common mutations with a small effect combined with many rare 
ones with a stronger effect), various environmental influences and epigenetic effects (van OS 
& Kapur, 2009; Owen et al., 2009; O’Donnel et al., 2009; Psychiatric GWAS Consortium 
[PGC], 2009; Roth et al., 2009). Over the years, multiple theories have been proposed to 
explain how these factors may generate schizophrenia. The different models proposed 
include principally the neurodevelopmental and the dopaminergic hypotheses which have 
been reviewed elsewhere (Fatemi & Folsom, 2009; Howes & Kapur, 2009). These two 
hypotheses may not necessarily be mutually exclusive as, for instance, a local dysfunction in 
dopaminergic neurotransmission may be the result of a failed development. Moreover, a 
number of studies pointed to the role of neurotrophins in the pathogenesis of schizophrenia.  
Neurotrophins are a small group of secreted dimeric proteins that affect the development of 
the nervous system in all vertebrates' species and are involved in the development and 
maturation of several brain networks including the dopaminergic system (Buckley et al. 
2007; Shoval & Weizman, 2005; Thome et al. 1998). Brain-Derived Neurotrophic Factor 
(BDNF) is the most widely distributed neurotrophin in the central nervous system (CNS) 
and is known to exert growth and trophic effects able to support many aspects of neuronal 
development including axonal growth and connectivity (Segal et al., 1995), neuronal 
survival and apoptosis (Segal et al., 1997), and formation of dopaminergic-related systems. 
Furthermore, BDNF has a dynamic effect on synaptic organization, promoting long-term 
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changes of synaptic transmission (Shen et al., 1997), as well as learning and memory 
processes (Yamada et al., 2002). For these reasons many studies investigated the role of 
BDNF in the pathophysiology of schizophrenia but their findings resulted contradictory. For 
example, some postmortem studies conducted on schizophrenia brains showed elevated 
BDNF levels in the anterior cingulate, hippocampus (Takahashi et al., 2000) and cerebral 
cortex (Durany et al., 2001), whereas others found decreased BDNF levels in the 
hippocampus (Durany et al., 2001) and prefrontal cortex (Weickert et al., 2003, 2005).  
Interestingly, in both humans and rodents, BDNF is present not only in the brain but also in 
peripheral tissues and especially, in the blood (Pruunsild et al., 2007; Aid et al., 2007). The 
origin of circulating BDNF has been debated as this neurotrophin is produced by many 
different body tissues and epithelia, including smooth muscle cells of blood vessels 
(Donovan et al., 1995). However, it has been demonstrated that radiolabeled BDNF injected 
in the jugular vein or in the brain ventricle readily crosses the blood-brain barrier in both 
directions (Pan et al., 1998) and can be taken up by platelets that function as storage and 
release system (Karege et al., 2005). In addition, it has been shown that physical exercise 
induces an increase of serum BDNF levels which is contributed by 70% from the brain 
(Rasmussen et al., 2009). Thus, measurement of circulating BDNF is very attractive, because 
it may provide information on brain functioning and blood samples are largely available 
and may be drawn non-invasively from living subjects as frequently as necessary. BDNF can 
be measured using simple enzyme linked immunoadsorbent assays (ELISA) that are 
commercially available and recent methodological studies have pointed out the possibility 
to obtain reliable measures of BDNF in serum preparations with stable values over several 
months of serum storage at -20°C, while in contrast, there is high variability in the measures 
of BDNF in whole blood or plasma because of the presence of release from platelets and 
degradation processes that are active even during storage (Elfving et al, 2009; Trajkovska et 
al., 2007). For these reasons, there is currently a great interest to validate the use of serum 
BDNF as possible biomarker in brain diseases, including psychiatric illnesses (for a recent 
meta-analisis of serum BDNF in depression see: Sen et al., 2008). 
To assess if BDNF can represent a good biomarker in schizophrenia, a growing number of 
studies compared BDNF serum levels between patients with schizophrenia and healthy 
control subjects but unfortunately, with controversial results. Indeed, several investigators 
found a significant decrease in serum BDNF concentrations  (Carlino et al., 2011; Chen et al., 
2009; Grillo et al., 2007; Ikeda et al., 2008, Jindal et al., 2010; Pirildar et al., 2004; Rizos et al., 
2008; Shimizu et al., 2002; Tan et al., 2005a, 2005b; Toyooka et al., 2002; Xiu et al., 2009; Zhang 
et al., 2007, 2008); while other studies documented normal (Shimizu et al., 2003; Jockers-
Schrubl et al. 2004; Huang et al. 2006) or even increased circulating BDNF (Gama et al., 2007; 
Reis et al., 2008). Because of these discrepancies, we decided to perform a systematic review 
and a meta-analysis of studies measuring serum concentrations of BDNF to elucidate whether 
or not this neurotrophin is abnormally produced in patients with schizophrenia. Additionally, 
we were interested in identifying factors that might contribute to the different findings in 
literature, as to improve the design of future investigations in this field. 
2. Methods 
2.1 Search strategy 
The PUBMED, OVID MEDLINE, PSYCHINFO and EMBASE databases were searched using 
the following medical subject headings (MeSH): “Brain-Derived Neurotrophic Factor” OR 
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“BDNF” AND “schizophrenia”. In addition, all reference lists of the selected papers were 
examined for studies not indexed electronically. The search aimed to find all papers 
published through January 2011.We used the PRISMA guidelines to carry out this review 
(Figure 1). 
2.2 Inclusion/exclusion criteria for both the systematic review and meta-analysis 
Studies had to fulfill the following inclusion criteria : 
1. Investigation of serum BNDF levels in patients with schizophrenia and healthy 
comparison subjects. 
2. Mean serum BDNF reported (ng/ml or pg/ml). 
3. Clinical characterization of patients with schizophrenia according to DSM-IV, ICD-10 or 
an equivalent system employed as a diagnostic tool. Study samples including some 
schizoaffective or schizophreniform subjects were also considered. 
4. Published in English. 
Exclusion criteria comprised: 
1. Samples including non-schizophrenia psychosis or other schizophrenia spectrum 
disorders. 
2. Plasma BDNF levels were measured. 
3. Publications describing case reports or case series. 
4. Patients or comparison subjects with neurological or medical disorders or substance or 
alcohol abuse. 
5. Comparison subjects screened for psychiatric disorders. 
In addition, in the studies exploring the same subject population or part of it, only the 
publication with the largest sample size was selected. When necessary, study Authors were 
contacted and asked to supply for missing or incomplete information. 
2.3 Data abstraction and quality rating 
Each paper was scrutinized by two independent reviewers (D.C. and M.B.) separately, and 
the following data from the article was obtained: age, gender, education, age at onset, 
duration of illness, number of hospitalizations, medications used (type, dosage and duration 
of treatment) and laboratory parameters. Mean serum BDNF levels (expressed in ng/ml) 
and the methods used for statistical analyses were also extracted from the article. 
Furthermore, the reviewers rated the quality of each study using a modified version of the 
quality rating check-list reported on Baiano et al. (2007). 
Category 1: subjects 
1. Prospective evaluation of patients, use of specific diagnostic criteria and description of 
demographic data; 
2. Prospective evaluation of healthy control subjects, description of demographic data, 
exclusion of psychiatric and medical illnesses; 
3. Presentation of significant variables (e.g. age, gender, age at onset, duration of illness, 
number of hospitalizations, medications used); 
Category 2: methods for sampling and analysis 
1. Clear description of laboratory technique and measurements, such in a way to be 
reproducible; 
2. Blindness of investigators to experimental setup; 
3. Report of intra and inter-assay reliability; 
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Category 3: results and conclusions 
 Use of appropriate statistical tests; 
 Presentation of main results and parameters for statistical significance; 
 Consistence of conclusions with the results and discussion of study limits. 
Each item was scored 1, 0.5 or 0 if criteria were completely met, partly met or unmet, 
respectively. This procedure was performed to evaluate the completeness of the available 
publications and not to criticize the investigations per se. 
 
 
Fig. 1. Flowchart of results of systematic review and meta-analysis search strategy. 
2.4 Statistical analysis 
The calculations were performed by means of the statistical software package STATA 8.0 
(StataCorp LP, Texas). Data were analyzed by using a random effects model (Metan 
command), which typically takes into account the between study variability, leading to wider 
confidence intervals than those obtained by a fixed effects model. Thus, studies were 
weighted for the inverse variance, obtaining the DerSimonian-Laird’s effect size (Deeks et 
al., 2001). Heterogeneity between studies was explored using the Q-test. Since we 
hypothesized a statistically significant heterogeneity, a meta-regression analysis was 
planned to assess the effects of selected factors (i.e.: gender distribution, ethnicity, ELISA kit 
used and average age) on results between studies (Metareg command). Publication bias was 
assessed by Egger’s tests (Egger et al., 1997) (Metabias command). All p values were two sided 
and the cutoff for statistical significance was 0.05. 
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3. Results 
3.1 Systematic review 
A total of 334 references were obtained. All the studies found in PUBMED database 
overlapped with those retrieved using OVID MEDLINE and PSYCHINFO databases. A total 
of 1036 references were identified. All the studies found in PUBMED database overlapped 
with those retrieved using OVID MEDLINE, EMBASE, PSYCHINFO lists. Most of them 
(322) did not meet the inclusion criteria, most analyzing val66met BDNF polymorphism, 
mRNA expression or post-mortem studies. 
Thus, 17 were finally considered but 16 were actually included in the systematic review 
(Carlino et al., 2011; Chen et al., 2009; Gama et al., 2007; Grillo et al., 2007; Huang et al., 2006; 
Ikeda et al., 2008; Jindal et al., 2010; Jockers-Schrübl et al., 2004; Pirildar et al., 2004; Reis et 
al., 2008; Rizos et al., 2008; Shimizu et al., 2003; Tan et al., 2005a; Toyooka et al., 2002; Xiu et 
al., 2009; Zhang et al., 2008). Indeed, as per Authors suggestion, we excluded the study by 
Zhang et al. (2007) (124 patients and 50 controls) since the patients’ sample consistently 
overlapped with that of the study published by Zhang and co-workers in the 2008 (196 
patients and 50 controls). 
3.1.1 Findings 
Most of the studies (12/16) measuring serum BDNF documented lower concentrations of 
this neurothropin in patients with schizophrenia (Carlino et al., 2011; Chen et al., 2009; 
Grillo et al., 2007; Ikeda et al., 2008; Jindal et al., 2010; Jockers-Schrübl et al., 2004; Pirildar et 
al., 2004; Rizos et al., 2008; Tan et al., 2005a; Toyooka et al., 2002; Xiu et al., 2009; Zhang et 
al., 2008); however, in other studies, BDNF concentrations were either increased (Gama et 
al., 2007; Reis et al., 2008); or normal (Huang et al., 2006; Shimizu et al., 2003) (Table 1). 
Five out of the 16 researches investigated gender effects, demonstrating either significantly 
lower (Xiu et al., 2009) or higher serum BDNF levels in males suffering from schizophrenia 
(Gama et al., 2007). Conversely, no gender effect emerged in Carlino et al., (2011), Huang et 
al. (2006) and Rizos et al. (2008) and in all healthy control subjects.  
3.1.2 Clinical features of patients 
15/16 studies reported on the mean age of the patients with schizophrenia (mean: 
37.229.48 SD years; range: 22.4-52.3). Nine studies provided data for age of onset of 
schizophrenia (mean: 25.704.86 SD years; range: 19.93-33.8) and 13 for length of illness 
(mean: 180.13127.65 SD months; range 8.8-388.8). Six out of 16 papers reported on the mean 
dosage of antipsychotic medications, expressed as chlorpromazine equivalents (mean: 
581.12219.90 SD; range:330.4-936.6). In one paper (Zhang et al., 2008), data for other 
psychopharmacological treatment (lithium, valproic acid) were included, but there were no 
details about the role of these drugs on serum BDNF levels.  
Only Jockers- Schrübl et al. (2004) evaluated the role of substance abuse (cannabis) in serum 
BDNF levels: the Authors found significantly elevated BDNF serum concentrations (by up 
to 34%) in patients with chronic cannabis abuse or multiple substance abuse prior to disease 
onset. Drug-naïve schizophrenic patients without cannabis consumption showed similar 
results to normal controls and cannabis controls without schizophrenia.  
In relation to the source of recruitment, 6/16 studies included only inpatients (Chen et al., 
2009; Reis et al., 2008; Rizos et al., 2008; Tan et al., 2005a; Xiu et al., 2009; Zhang et al., 2008), 
1/16 included only outpatients (Gama et al., 2007), 3/16 considered both in-patients and 
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out-patients (Carlino et al., 2011; Huang et al., 2006; Ikeda et al., 2008) and 6/16 publications 
did not provide data (Grillo et al., 2007; Jindal et al., 2010; Jockers-Schrübl et al., 2004; 
Pirildar et al., 2004; Shimizu et al., 2003; Toyooka et al., 2002). In our research, we found that 
Japanese subjects were investigated in three studies (Ikeda et al., 2008; Shimizu et al., 2003; 
Toyooka et al., 2002), Caucasians in another four studies (Carlino et al., 2011; Jockers- 
Schrübl et al., 2004; Pirildar et al., 2004, Rizos et al., 2008) and Asians in five studies (Chen et 
al., 2009; Huang et al., 2006; Tan et al., 2005a, Xiu et al., 2009, Zhang et al., 2008). In four 
studies, ethnicity was unspecified (Gama et al., 2007; Grillo et al., 2007, Reis et al., 2008; 
Jindal et al., 2010). 
Six studies reported no diagnostic subtypes of schizophrenia (Ikeda et al., 2008; Gama et al., 
2007; Jockers- Schrübl et al., 2004; Pirildar et al., 2004;Reis et al., 2008; Rizos et al., 2008; 
Toyooka et al., 2002) while in seven studies it was assessed the differences in serum BDNF 
levels among diagnostic subtypes (Chen et al., 2009; Grillo et al., 2007; Huang et al., 2006; 
Shimizu et al., 2003; Tan et al., 2005a; Xiu et al., 2009; Zhang et al., 2008). Different forms of 
schizophrenia had no association with BDNF serum levels in 5 papers (Grillo et al., 2007, 
Shimizu et al., 2003; Tan et al., 2005a; Xiu et al., 2009; Zhang et al., 2008), while Chen et al. 
(2009) showed significantly higher BDNF levels in paranoid (10.4 ± 4.3 ng/ml) compared to 
undifferentiated (8.0 ± 3.9 ng/ml) and other combined subtypes (7.5± 4.1 ng/ml). Huang et 
al. (2006) showed that patients with catatonic schizophrenia had lower serum BDNF protein 
levels than patients with paranoid schizophrenia and residual schizophrenia. 
In a second step, phase of illness and use of antipsychotic drugs were considered. We found 
that four studies enrolled only drug-naïve first-episode patients (Chen et al., 2009; Jindal et 
al., 2010; Jockers-Schrübl et al., 2004; Rizos et al., 2008), eight studies recruited only chronic, 
medicated patients (Carlino et al., 2011; Gama et al., 2007; Ikeda et al., 2008; Reis et al, 2008; 
Tan et al., 2005a; Toyooka et al., 2002; Xiu et al., 2009; Zhang et al., 2008) and two studies 
included medicated patients with unclear phase of illness (Grillo et al., 2007; Huang et al., 
2006). Notably, the study by Pirildar et al. (2004) and Shimizu et al. (2003) investigated both 
chronically antipsychotic-treated and drug-naïve patients; in particular, in Pirildar et al. 
(2004) some first episode medicated subjects were included. All the 16 studies excluded 
patients with a history of neurological disease, physical illness, and alcohol or substance 
abuse. Clinical data are summarized in Table 2. 
3.1.3 Serum BDNF concentrations and laboratory procedures 
Among studies, laboratory procedures were comparable with some minor variations. Sera 
were centrifuged to eliminate the blood clot with a mild centrifugation at 2000, 3000 or 3500 
rpm for 5-15min at room temperature or 15°C); then, they were stored frozen at -70/-80°C 
until used. Serum BDNF concentrations were measured using sandwich ELISA assays (see 
Table 1 for full detail). Finally, all the studies except one (Gama et al., 2007) reported clearly 
on mean BDNF concentrations. Specifically, mean serum BDNF values were 14.4310.24 SD 
ng/ml (range: 0.098-37.1) for patients and 17.9913.41 SD ng/ml, (range: 0.12-52.2) for 
healthy blood donors.  
3.1.4 Study quality 
The mean total quality scores for the reports were 7.63±1.17 SD (min.:5.5; max.: 9). We 
correlated total and partial quality scores of studies on serum BDNF with the year of 
publication, which was significantly positively correlated to total quality score (r=0.53) and 
www.intechopen.com
 
State of Art of Serum Brain-Derived Neurotrophic Factor in Schizophrenia 
 
73 
study methodology score (Category 2) (r=0.59) but not to study design score (Category 1) 
(r= -0.20) or study consistency score (Category 3) (r=0.27). 
 
Authors ELISA kit 
Quality 
of rating 
(QR) 
Control Schizophrenic patients 
Serum 
BDNF 
(mean 
ng/ml + SD)
Serum 
BDNF 
(mean 
ng/ml + 
SD) 
Medication 
Toyoka 
et al., 2002 
Sigma 
Chemical 
6.5 11.4 + 7.7 6.3 + 3.4 
29=haloperidol, 
5=chlorpromazine, 
31=levomepromazine, 
2=zotepin, 3=bromperidol, 
1=risperidone,  
9=other 
Ikeda et al., 
2003 
Promega 9 52.2 + 25.3 37.1 + 20.4
Typical and atypical (dose 
not available) 
Shimizu 
et al., 2003 
(part I) 
Promega 
6.5 28.5 + 9.1 27.9 + 12.3
---- 
Shimizu 
et al., 2003 
(part II) 
6.5 28.5 + 9.1 23.8 + 8.1 
Pirildar 
et al., 2004 
(part I) 
Promega 
8 26.8 + 9.3 14.4 + 2.8 
17=risperidone, 
2=clozapine, 
3=olanzapine 
Pirildar 
et al., 2004 
(part II) 
8 26.8 + 9.3 16.3 + 4.0 
Jockers-
Schrübl 
et al., 2004 
Promega 6.5 13.2 + 5.2 13.1 + 5.9 ---- 
Tan 
et al., 2005 
BanDing 
Biomedical
9 9.1 + 4.3 5.8 + 2.1 
38=clozapine, 
19=risperidone, 
12=haloperidol, 
5=chlorpromazine, 
5=perphenazine, 
2=others (n = 2) 
Huang 
et al., 2006 
Promega 5.5 14.17 + 6.9 14.2 + 6.9 ---- 
Grillo 
et al., 2007 
Chemicon 8 0.17 + 0.0 0.11 + 0.1 
20=Clozapine; 
24=typical antipsychotics; 
6=chlorpromazine; 
15=levomepromazine; 
5=haloperidol 
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Authors ELISA kit 
Quality 
of rating 
(QR) 
Control Schizophrenic patients 
Serum 
BDNF 
(mean 
ng/ml + SD)
Serum 
BDNF 
(mean 
ng/ml + 
SD) 
Medication 
Zhang 
et al., 2008 
BanDing 
Biomedical
7.5 9.4 + 4.4 7.0 + 3.1 
98=clozapine, 
36=risperidone, 
20=perphenazine, 
19=haloperidol, 
14=chlorpromazine, 
9=fluphenazine, 
9=trifluperazine 
Reis 
et al., 2008 
R&D 
Systems 
6 4.31 + 2.1 7.75 + 1.9 
28=haloperidol, 
3=chlorpromazine, 
3=levoepromazine, 
6=trifluorperazine 
Rizos 
et al., 2008 
R&D 
Systems 
7 30.0 + 8.4 23.9 + 6.0 ---- 
Xiu 
et al., 2009 
BanDing 
Biomedical
9 11.9 + 2.3 9.9 + 2.0 
157=Clozapine, 
89=risperidone, 
31=haloperidol, 
21=chlorpromazine, 
26=perphenazine, 
27=sulpiride,  
13=other 
Chen 
et al., 2009 
BanDing 
Biomedical
8.5 12.1±2.2 9.0±4.2 ---- 
Jindal 
et al., 2010 
Promega 9 116.78±38.42 97.58±31.41 ---- 
Carlino 
et al., 2011 
Promega 9 26.5 ± 4.22 25.3 ± 3.71
4=haloperidol, 
2=zuclopenthixol, 
2=haloperidol decanoate, 
10= olanzapine, 
6=risperidone, 
8=quetiapine, 
1=olanzapine 
+zuclopenthixol , 
2=olanzapine 
+haloperidol, 
2=quetiapine 
+haloperidol,2= 
quetiapine 
+zuclopenthixol, 
3=risperidone+haloperidol 
Table 1. Methodological aspects of the studies measuring serum BDNF in schizophrenia. * 
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3.1.5 Meta-analysis 
Fifteen out of the 16 publications considered for the systematic review were used for the 
meta-analysis (Carlino et al., 2011; Chen et al., 2009; Grillo et al., 2007; Huang et al., 2006; 
Ikeda et al., 2008; Jindal et al., 2010; Jockers-Schrübl et al., 2004; Pirildar et al., 2004; Reis et 
al., 2008; Rizos et al., 2008; Shimizu et al., 2003; Tan et al., 2005a; Toyooka et al., 2002; Xiu et 
al., 2009; Zhang et al., 2008). The study by Gama et al., (2007) was eliminated, as it was the 
only one to report serum BDNF in pg/μg of total protein while in all other studies serum 
BDNF concentration was given in ng or pg/ml serum and therefore, no comparison 
between the Gama’s and the other studies was possible. Since the studies by Shimizu et al., 
(2003) and Pirildar et al., (2004) reported on separate data for both medicated and 
unmedicated patients, we performed calculations considering patients’ subgroups as 
follows: Shimizu et al., 2003 part I and Pirildar et al., 2004 part I = medicated patients; 
Shimizu et al., 2003 part II and Pirildar et al., 2004 part II = unmedicated patients. Therefore, 
we carried out calculations on 17 samples of patients.  
 
Authors 
Stages of 
disease 
Ethnicity
* 
Control Schizophrenic patients 
N 
Age 
(mean 
 + SD) 
M/F N 
Age 
(mean 
+ SD) 
M/F 
Illness 
duration 
(mean-
months  
+ SD) 
Toyoka  
et al., 2002 
Chronic JPT 35 
45.6  
+ 11.3 
14/21 34 
48.6  
+ 14.0 
17/17 25+12.3 
Ikeda  
et al., 2003 
Chronic JPT 87 
39.8 
 + 10.7 
47/40 74 
41.9 
 + 11.1 
39/35 19.6+11.2 
Shimizu 
et al.,2003 
(part I) 
Chronic JPT 40 
36.5  
+ 11.3 
20/20 25 
36.0  
+ 13.2 
13/12 Med scz: 
14.1+9.87; 
FEP: 
1.09+1.36 
Shimizu 
et al.,2003 
(part II) 
First 
episode/
drug naïve
JPT 40 
36.5  
+ 10.7 
20/20 15 
34.7  
+ 16.0 
7/8 
Pirildar  
et al., 2004 
(part I) 
Chronic CEU 22 
25.7  
+ 5.8 
7/15 12 
29.8  
+ 9.3 
5/7 
15.2±13.04 
Pirildar  
et al., 2004 
(part II) 
First 
episode/
drug naïve
CEU 22 
25.7  
+ 5.8 
7/15 10 
25.1  
+ 9.1 
2/8 
Jockers-
Schrübl 
et al., 2004 
First 
episode/
drug naïve
CEU 61 32.3 28/33 102 33.3 50/52 ---- 
Tan  
et al., 2005 
Chronic CHB 45 
45.6  
+ 6.3 
34/11 125
18.3  
+ 6.3 
93/32 22.6±7.7 
Huang  
et al., 2006 
Chronic CHB 96 
29.1  
+ 10.0 
36/60 126
34.0  
+ 10.0 
72/54 6.0±5.0 
Grillo  
et al., 2007 
Chronic 
YRI/CEU
(ratio not 
specified)
25 
34.1  
+ 7.2 
12/13 44 
35.5  
+ 7.2 
19/25  
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Authors 
Stages of 
disease 
Ethnicity
* 
Control Schizophrenic patients 
N 
Age 
(mean 
 + SD) 
M/F N 
Age 
(mean 
+ SD) 
M/F 
Illness 
duration 
(mean-
months  
+ SD) 
Zhang et 
al., 2008 
Chronic CHB 50 ---- 34/16 196 ---- 130/66 
22 
± 7 
Reis  
et al., 2008 
Chronic 
YRI/CEU
(ratio not 
specified)
20 ---- 20/0 40 
52.3  
+ 9.8 
40/0 
32.4 
± 9.2 
Rizos 
et al., 2008 
First 
episode/
drug naïve
CEU 15 
26.6  
+ 5.8 
6/9 14 
25.4  
+ 5.8 
10/4 ---- 
Xiu  
et al., 2009 
Chronic CHB 323
50.9 
+ 9.2
228/95 364
51.3 
+ 9.2
281/83 
27.0 
± 10.1 
Chen  
et al., 2009 
First 
episode/ 
drug naïve
CHB 90 
29.9 
± 9.8 
49/41 88 
29.2 
± 9.6 
47/41 
23.4 
± 19.1 
Jindal  
et al., 2010 
First 
episode/ 
drug naïve
CEU 41 
22.31 
± 5.67 
25/16 24 
22.4 
± 5.47 
17/10 ---- 
Carlino  
et al., 2011 
Chronic CEU 40 
46.78 
± 10.79 
20/20 40 
49.23 
± 9.03
20/20 
23.05  
± 10.99 
Table 2. Clinical characteristics of studies included in the meta-analysis. International 
HapMap Project: YRI: Yoruba in Ibadan, Nigeria; JPT: Japanese in Tokyo; CHB: Han 
Chinese in Beijing, China; CEU: CEPH (Utah residents with ancestry from Northern and 
Western Europe). 
Raw total serum BDNF levels (ng/ml) were used to calculate the related effect sizes. The 
overall estimate of SMD (standardized mean differences) in serum BDNF levels between 
patients with schizophrenia and healthy controls was significant (z=4.14; p<0.001) but 
considerable heterogeneity emerged from publications (Q=139.15; d.f.=16; p<0.001; τ²= 
0.2826) (Figure 2).  
Therefore, we regressed the SMD against potential sources of heterogeneity (i.e.: gender, age, 
ethnicity and ELISA kit used). This analysis demonstrated a significant association of BDNF 
levels with all these variables (age: z=15.28; gender: z=10.92 for males; z=4.60 for females; 
ethnicity: Z=9.37 and ELISA kit: z=8.55; p<0.001). Moreover, to determine if this systematic 
review and meta-analyses was subjected to publication bias (i.e. the presence of asymmetrical 
collection of data due to the missing of studies reporting negative results, or to the tendency of 
small studies to show greater effects than larger studies), we carried out the Egger’s weighted 
regression and evidence of significant publication bias was found (p<0.001). Subsequently, the 
eleven studies investigating chronic, medicated patients with schizophrenia were considered 
(Carlino et al., 2011; Grillo et al., 2007; Huang et al., 2006; Ikeda et al., 2008; Pirildar et al., 2004 
part I; Reis et al, 2008; Shimizu et al., 2003 part I; Tan et al., 2005a; Toyooka et al., 2002; Xiu et 
al., 2009; Zhang et al., 2008). Significant heterogeneity was found (Q=120.85, d.f=10, p<0.001, 
τ²=0.3545) and patients and healthy control subjects differed for serum BDNF levels, as 
demonstrated by the SMD test (z=2.69; p=0.007) (Figure 3).  
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Standardised Mean diff.
-2 -1 0 21
Study  % Weight
 Standardised Mean diff.
 (95% CI)
 -0.85 (-1.35,-0.36) 1   5.9
 -0.06 (-0.56,0.44) 2   5.9
 -0.53 (-1.13,0.07) 3   5.4
 -0.02 (-0.33,0.30) 4   6.6
 -1.39 (-2.06,-0.72) 5   5.1
 -1.11 (-2.13,-0.09) 6   3.7
 -0.79 (-1.16,-0.41) 7   6.4
 0.00 (-0.26,0.27) 8   6.8
 -1.72 (-2.29,-1.15) 9   5.6
 -0.65 (-0.97,-0.33) 10   6.6
 1.79 (1.16,2.42) 11   5.3
 -0.83 (-1.59,-0.07) 12   4.7
 -0.71 (-1.02,-0.39) 13   6.6
 -0.93 (-1.24,-0.62) 14   6.6
 -0.93 (-1.09,-0.77) 15   7.1
 -0.62 (-1.13,-0.10) 16   5.8
 -0.91 (-1.37,-0.45) 17   6.0
 -0.59 (-0.87,-0.31) Overall (95% CI)
 
Fig. 2. Forrest plot depicting the meta-analysis of serum BDNF levels in patients with 
schizophrenia. 
 
Standardised Mean diff.
-2 -1 0 1 2
Study  % Weight
 Standardised Mean diff.
 (95% CI)
 -0.85 (-1.35,-0.36) 1   8.8
 -0.06 (-0.56,0.44) 2   8.8
 -1.39 (-2.06,-0.72) 3   7.8
 -0.79 (-1.16,-0.41) 4   9.4
 0.00 (-0.26,0.27) 5   9.9
 -1.72 (-2.29,-1.15) 6   8.4
 -0.65 (-0.97,-0.33) 7   9.7
 1.79 (1.16,2.42) 8   8.1
 -0.71 (-1.02,-0.39) 9   9.7
 -0.93 (-1.09,-0.77) 10  10.2
 -0.30 (-0.74,0.14) 11   9.1
 -0.52 (-0.89,-0.14) Overall (95% CI)
 
Fig. 3. Forrest plot presenting the meta-analysis of serum BDNF in chronic medicated 
patients with schizophrenia. 
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6. Grillo et al.,2007
7. Ikeda et al.,2008
8. Reis et al.,2008
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11. Carlino et al.,2011
11. Reis et al.,2008 
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1. Toyooka et al., 2002 
5. Pirildar et al.,2004 (I) 
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8. Huang et al.,2006 
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10. Ikeda et al.,2008
12. Rizos et al.,2008
14. Chen et al.,2009
15. Xiu et al.,2009 
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Standardised Mean diff.
-2 -1 0 1 2
Study  % Weight
 Standardised Mean diff.
 (95% CI)
 -0.53 (-1.13,0.07) 1  16.0
 -0.02 (-0.33,0.30) 2  21.8
 -1.11 (-2.13,-0.09) 3   9.4
 -0.83 (-1.59,-0.07) 4  13.1
 -0.93 (-1.24,-0.62) 5  22.0
 -0.62 (-1.13,-0.10) 6  17.7
 -0.62 (-1.01,-0.22) Overall (95% CI)
 
Fig. 4. Forrest plot presenting the meta-analysis of serum BDNF in unmedicated patients 
with schizophrenia. 
The meta-regression analysis showed that age (z=13.89), gender (z=11.09 for males; z=7.36 
for females), ethnicity (z=6.76), type of ELISA kit (z=6.67), chlorpromazine equivalents’ 
medication dosage (z=5.97) and duration of illness (z=7.03) may all explain heterogeneity 
(p<0.001). Similar results were obtained by meta-analyzing the six studies including first-
episode unmedicated patients (Chen et al., 2009; Jindal et al., 2010; Pirildar et al., 2004; Rizos 
et al., 2008; Shimizu et al., 2003 part II) (Figure 4). Indeed, we found that both the Q test for 
heterogeneity (Q=18.30; d.f =5; p=0.003; τ²=0.1595) and Dersimonian and Laird pooled effect 
size (z=3.06, p=0.002) were significant. As previously demonstrated, heterogeneity may be 
due to age (z=15.33), gender (z=4.55 for males; z=4.84 for females), ethnicity (z=5.47), type of 
ELISA kit (z=4.45). 
4. Conclusion  
Our systematic review and meta-analysis showed that lower serum BDNF levels were 
detected in patients with schizophrenia in comparison to healthy controls in most even if 
not in all studies. Interestingly, reduced serum BDNF levels were found both in drug-naïve 
first episode and chronic medicated schizophrenia patients, as also found in studies 
investigating plasma BDNF concentrations (Buckely et al., 2007; Palomino et al., 2006; Tan et 
al., 2005b). These findings show that reduced serum BDNF levels are associated with 
schizophrenia but also suggest that serum BDNF is not a crucial biological marker of the 
clinical state in schizophrenia or a marker of antipsychotic medication efficacy, in agreement 
with a recent meta-analysis (Green et al., 2010).  
The serum BDNF concentration in healthy populations, varied from a minimum of 0.17 
ng/ml (Grillo et al., 2007) to a maximum of 52.2 ng/ml (Ikeda et al., 2003), the mean value 
among the thirteen paper analysed was 16.2 ng/ml (SD=14.59). Although we observed 
variability between studies using the same commercial ELISA, differences in serum BDNF 
concentration appeared mainly due to the different kit used. For example the three studies 
1. Shimizu et al.,2003 (II) 
2. Jocker-Schrübl et al., 2004 
3. Pirildar et al.,2004 
(II) 
4. Rizos et al., 2008 
5. Chen et al., 2009 
6. Jindal et al., 
2010
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which used the kit purchased from BanDing Biomed reported values of serum BDNF in 
Chinese healthy donors of 11.9 + 2.3 ng/ml (Xiu et al., 2009); 9.4 + 4.4 ng/ml (Zhang et al., 
2008); 9.1 + 4.3 ng/ml (Tan et al., 2005) while higher levels of serum BDNF were detected 
with the kit from Promega in healthy donors from Japan, 28.5 + 9.1 ng/ml (Shimizu et al., 
2003); Turkey 26.8 + 9.3 ng/ml (Pirildar et al., 2004) and Taiwan 14.17 + 6.9 ng/ml (Huang 
et al., 2006). Finally, two studies using the R&D System ELISA assay showed very distant 
results because Rizos et al. (2008) detected 30.0 + 8.4 ng/ml of serum BDNF in healthy 
controls from Greece while Reis et al., (2008) in Brazil, found 4.31 + 2.1 ng/ml. Two other 
studies from Brazil also showed particularly low levels using the assay from another 
company (Chemicon), i.e. 0.19 + 0.1 ng/ml (Gama et al., 2007) and 0.17 + 0.0 ng/ml (Grillo 
et al., 2007). It is possible that this finding might reflect reduced amounts of serum BDNF 
in the Brazilian population. Another interpretation suggests a very low sensitivity of the 
ELISA kit from Chemicon. In conclusion, the most likely range of concentrations of serum 
BDNF in the World healthy population is 9-30 ng/ml with some possible specific regional 
variations. 
However, the great heterogeneity between studies and the presence of a publication bias 
may limit the interpretation of these results. Firstly, the phenotypic complexity, together 
with the multifarious nature of the so-called “schizophrenic psychoses”, limits our ability to 
form a simple and logical, biologically-based hypothesis for the disease group. Secondly, all 
studies used ELISA assays that have different sensitivity and cannot distinguish between 
the three different protein forms of BDNF consisting in the precursor pro-BDNF (of 32 KDA) 
and its two proteolytic products mature BDNF (mBDNF of 14KDa) and truncated BDNF 
(truncBDNF of 28 KDa). Since pro-BDNF and mBDNF elicit opposing actions on synaptic 
plasticity and cell survival, their distinction could be essential to determine the role of BDNF 
in specific aspects of schizophrenia’s neurobiology.  
4.1 The role of proBDNF in patients with schizophrenia  
BDNF is initially synthesized as a 32 KDa precursor protein (prepro-BDNF) in endoplasmic 
reticulum, and then processed into two isoforms (as the truncated-BDNF 28 KDa and 
mature 14 kDa BDNF) by two different proteolitic cleavages. Mature BDNF (mBDNF) is 
generated either intracellularly in the trans-Golgi by furin (Mowla et al., 2001, Matsumoto et 
al., 2008), or extracellularly by plasmin or matrixmetalloprotease-7 (Lee et al., 2001, Yang et 
al. 2009; Nagappan et al., 2009). Truncated-BDNF is cleaved by the Membrane-Bound 
Transcription Factor Site-1 protease (MBTFS-1), also identified as Subtilisin/kexin-isozyme 1 
(Seidah et al., 1999). This isoform is not further processed into mBDNF and its function has 
not been elucidated yet. 
According to the “Ying and Yang” hypothesis (Lu et al., 2005), both mBDNF and proBDNF 
have particular neurobiological properties. In particular, proBDNF regulate neuronal 
survival (Teng et al., 2005; Koshimizu et al., 2009; Woo et al., 2005) and boosts synaptic 
pruning whereas mBDNF improves the differentiation of new neurons. Also, the conversion 
of proBDNF into mBDNF seems to be decisive for signal transmission and synaptic 
plasticity. Indeed, mBDNF and the Tissue Plasminogen Activator (TPA) but not proBDNF 
are essential in late-phase long-term potentiation (L-LTP) and long-term memory (Pang et 
al., 2004). These results underscore that a wrong matching of the proBDNF/mBDNF ratio 
may alter neuroplastic mechanisms, corresponding to the neurobiological substrate of 
impaired cognitive performance. 
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An increasing number of postmortem researches have been carried out to measure the 
expression of proBDNF and mBDNF isoforms in animal models and in healthy human 
volunteers or subjects affected by neuropsychiatric disorders. Reduced mBDNF levels were 
found in three studies (Karege et al., 2005; Weickert et al., 2003; Wong et al., 2010), 
particularly in the dorsolateral prefrontal cortex (DLPFC) of patients with schizophrenia 
compared to healthy controls. Weickert et al. (2003) found that mBDNF protein levels were 
not associated with post-mortem interval (PMI), tissue pH, age, or storage time of the 
serum. There were no significant main influences of gender or brain hemisphere, nor 
significant correlations between diagnosis and gender or diagnosis and brain hemisphere. 
On the other hand, Chen et al. (2001) showed that there was no significant variation for 
mBDNF among patients with schizophrenia and those with a diagnosis of affective 
disorders (unipolar and bipolar disorders) and Dunham et al., (2009) detected no difference 
for preproBDNF (35KDa) between patients with schizophrenia and those with unipolar 
depression and bipolar disorder. In contrast, Wong et al. (2010) found reduced truncated 
BDNF and preproBDNF proteins in the DLPFC of patients with schizophrenia, even if the 
reduction in preproBDNF protein did not achieve statistical significance. 
In a previous study (Carlino et al., 2011), we provided evidence of variation in serum levels 
of different BDNF isoforms in patients with chronic schizophrenia. Particularly, we showed 
that reduced levels of serum truncated-BDNF/total BDNF ratio correlate with worst PANSS 
negative and positive symptoms and poorer neurocognitive functions. Instead, 
measurement of total serum BDNF levels resulted scarcely useful, even if we found a small 
decline in the whole population of schizophrenic patients. We further highlighted that when 
using a cut-off at the mean value of the healthy group + 2SD, the measurement of serum 
truncated-BDNF represents a useful empirical test to recognize schizophrenic patients with 
high cognitive impairment, with sensitivity = 67.5%, Specificity = 97.5%, PPV = 96.4% and 
NPV = 75%. 
Regulated proteolysis of one inactive precursor to make active peptides and proteins is a 
general biological mechanism to generate different products from a single gene. Mammalian 
pro-BDNF precursor is processed to generate truncated-BDNF 28 KDa or mature 14 kDa 
BDNF by two dissimilar proteolitic cleavages. Mature BDNF is created intracellularly by 
furin (Mowla et al., 2001), or extracellularly, by plasmin or matrixmetalloprotease-7 (Lee et 
al., 2001), whereas truncated-BDNF is generated by a specific Ca2+dependent serine 
proteinase known as Membrane-bound transcription factor site-1 protease (MBTFS-1), also 
identified as Subtilisin/Kexin-Isozyme 1 (SKI-1) (Seidah et al., 1999); it is not further 
processed into the mature 14 kDa BDNF form representing a final proteolytic product 
whose role is ambiguous. Recent findings have established that mature and pro-BDNF elicit 
opposite biological functions (Teng et al., 2005; Woo et al., 2005), leading to the hypothesis 
that from an incorrect balancing of the diverse isoforms may origin a pathological 
consequence. In recent times, Koshimizu et al. (2009) pointed out that overexpression of pro-
BDNF leads to apoptosis of cultured cerebellar granule neurons and produce a striking 
decrease in the number of cholinergic fibers of basal forebrain neurons and hippocampal 
dendritic spines, without disturbing the survival of these neurons. Blockade of activation of 
p75 receptor did not permit spine number to fall. Importantly, the pro-BDNF preparation 
used in this paper contained a large amount of truncated-BDNF, although at a much lesser 
extent than pro-BDNF. It is therefore possible that truncated-BDNF may have a similar 
outcome than pro-BDNF through activation of the same signalling pathways. Alternatively, 
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truncated-BDNF may be an inactive variety of pro-BDNF or operate as a quencher of pro-
BDNF by producing inactive heterodimers. The latter possibility reminds the supposed 
function for truncated-TrkB. Hence, a clear decrease in truncated-BDNF may direct to 
pathologically amplified signalling of pro-BDNF. Further studies will be necessary to clarify 
the biological characteristics of truncated-BDNF. 
Chronic patients with schizophrenia are often characterized to suffer progressive significant 
intellectual decline (Heinrichs, 2006). In our study, schizophrenic patients with reduced 
truncated-BDNF had worse efficency in all neurocognitive tests in relationship to the other 
patients with normal levels of truncated-BDNF, although the correlation between Trail 
Making Test Part A score and truncated- BDNF abundance do not reach the statistically 
significance. Our results further enlarge a recent research telling that evaluation of total 
serum BDNF may be useful to predict for a good outcome in neurocognitive enhancement 
sessions in schizophrenic patients (Vinogradov et al., 2009). Importantly, we also underline 
that four healthy subjects with low truncated-BDNF had poor scores in Trail Making Test B 
and Symbol Digit Coding attention test. So we can hypothesize that schizophrenic patients 
with low serum truncated-BDNF and worse cognitive functioning are likely to be more 
resistant to a non-psychopharmacological neurocognitive training. 
On the basis of these findings, we sharpen the role of evaluation of serum BDNF as an 
empirical system to estimate cognitive defects related to proBDNF processing as a potential 
biological system basic in the pathophysiology of schizophrenia. 
4.2 The role of ethnic differences in serum BDNF levels in patients with schizophrenia 
An element of heterogeneity that emerges from this meta-analysis is represented by the 
ethnic differences amongst the samples. In this context it is of great interest to note that there 
are divergent findings of the positive or negative associations between BDNF val66met 
polymorphism and schizophrenia, especially in Caucasian and Asian participants. These 
differences may partially explain the differences in serum BDDNF levels among papers. 
Studies in in vitro and in animal models have shown that Met allele alters both sorting and 
secretion of proBDNF, such that less regulated (activity dependent) secretion is likely to 
occur in carriers of at least one Met allele. Several genetic associational studies have shown 
that SNPs in BDNF are associated with schizophrenia (Nanko et al., 2003; Szekeres et al., 
2003), and a meta-analysis study also illustrated an association between C270T and 
schizophrenia (Zintzaras, 2007), but not between Val66Met and schizophrenia (Kanazawa et 
al., 2007; Naoe et al., 2007; Xu et al., 2007; Zintzaras, 2007). 
Great differences in the allelic frequencies for the BDNF Val66Met polymorphism between 
populations of different ethnic origins have been reported in public databases 
(http://www.hapmap.org) for the same populations (Tables 3 and 4). In Caucasian subjects, 
the frequency of the Met allele is 25–32%, whereas in Asian peoples the Met allele is more 
frequent, around 40–50% (Pivac et al., 2009; Verhagen et al., 2010). These variations among 
different ethnic groups in the allelic frequencies of the BDNF polymorphism may be caused 
by either the natural selection of an advantageous allele by unknown environmental issues 
or through a founder effect.  
However, we advise prudence in the analysis of these facts, also because despite this 
obvious difference in outcomes of schizophrenia across ethnicities, cross-cultural research in 
psychiatry focuses on similarities rather than differences. For example, subtypes of 
schizophrenia may have different prevalence across countries: in the International Pilot 
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Study of Schizophrenia (1973) and the Determinants of Outcome of Severe Mental Disorders 
study (1992), catatonia was identified in 10% of cases in developing countries respect to less 
than 1% in developed countries. Hebephrenia was found in 13% of cases in developed 
countries and 4% in developing countries. Currently, we have not sufficient data about the 
role of diagnostic subtypes and serum BDNF levels or BDNF polymorphisms. 
 
Genotype - Population descriptors Genotype frequencies 
G/G – YRI 0.683 
G/G – JPT 0.190 
G/G – CHB 0.488 
G/G – CEU 1.000 
A/G- YRI 0.283 
A/G- JPT 0.357 
A/G- CHB 0.349 
A/G- CEU n.a. 
A/A- YRI 0.033 
A/A- JPT 0.452 
A/A- CHB 0.163 
A/A- CEU 0 
Table 3. YRI: Yoruba in Ibadan, Nigeria; JPT: Japanese in Tokyo, Japan; CHB: Han Chinese 
in Beijing, China; CEU: CEPH (Utah residents with ancestry from northern and western 
Europe). G/G = Met/Met; A/G =Val/Met; A/A = Val/Val. 
 
Allele - Population descriptors Allele frequencies 
G- YRI 0.825 
G- JPT 0.369 
G- CHB 0.663 
G- CEU 1.000 
A- YRI 0.175 
A – JPT 0.631 
A- CHB 0.337 
A- CEU 0 
Table 4. YRI: Yoruba in Ibadan, Nigeria; JPT: Japanese in Tokyo, Japan; CHB: Han Chinese 
in Beijing, China; CEU: CEPH (Utah residents with ancestry from northern and western 
Europe). 
Another diagnostic caveats regards the Caucasian studies that often investigated not only 
patients with schizophrenia, but also subjects with schizophrenia spectrum disorders such 
as schizophreniform disorder or schizoaffective disorder, while Asian and other studies 
investigated only patients with schizophrenia. This difference in methodology might also 
have contributed to the inconsistent findings between the Caucasian and the Asian studies. 
The substantial variation in the Val66Met frequencies between Asian and Caucasian 
samples indicates that ethnicity may be of importance in the issue, because if the association 
among Caucasians reflects linkage disequilibrium with another gene variant, the extent of 
linkage may vary between populations. A recent study focused on the complex 
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microsatellite polymorphism BDNF-LCPR located ~1.0 kbp upstream of the translation 
initiation site of BDNF (Okada et al., 2006); this polymorphism contained 23 novel allelic 
variants, including four major alleles (A1–A4). Kawashima et al. (2009) consider that if 
BDNF is indeed associated with schizophrenia, the A1 allele in BDNF-LCPR would be a 
hopefully useful marker in the Japanese population. 
Also, we must not forget the interchange between genetic and environmental issues, that 
may essentially vary for men and women. In this regard, it would be interesting to evalute if 
gender-related epistatic effects pertaining to the Val66Met polymorphism subsist. Literature 
data showed that gender differences in schizophrenia reproduce divergences in 
neurodevelopmental mechanisms and social influences on illness risk and course. Men have 
poorer premorbid functioning and have worse negative and less depressive manifestations 
than women. Substance abuse is more frequent in male. Results of gender variations in brain 
morphology (e.g. hippocampal volume) are conflicting but refer to matter of sexual 
dimorphism, meaning that the same elements are significant to explain sex disparities in 
both normal neurodevelopment and those in relationship with schizophrenia.  
Another factor to consider is the epigenetic influence. “Epigenetic” refers to the covalent 
modifications of chromatin. Epigenetic machinery not only is responsible for lasting 
differences in gene activity in the CNS but also controls gene expression necessary for 
cognition. Thus, the likelihood of an epigenetic involvement in schizophrenia is an interesting 
hypothesis. In fact, epidemiological studies have identified several environmental risk factors 
for schizophrenia, counting marijuana consumption and obstetric complications. A recent 
study by Nicodemus and colleagues (2008) showed a significant association between four 
candidate genes for schizophrenia which are likely to have a role in hypoxic situations, 
including BDNF detecting significant evidence for gene x environment interaction in 
schizophrenic patients with or without obstetric complications. Recently, several studies 
underline that DNA methylation contributing to ongoing regulation of BDNF transcription in 
the CNS to control synaptic plasticity and memory mechanism (for e review, see Roth et al., 
2009a). In addition, BDNF DNA methylation has also been found to play a part in altered gene 
expression in response to environmental pressure, such as social experiences (Roth et al., 2009). 
Indeed, stressful social experiences early in life have long-lasting consequences such as 
increased anxiety, drug-seeking behavior, cognitive impairment, and altered affiliative 
behaviours (Branchi et al., 2004; Fumagalli et al., 2007; Lippmann et al., 2007). Finally, it was 
recently revealed that social experiences early during the first postnatal week generate lasting 
changes in DNA methylation in BDNF gene in relationship with reduction of BDNF gene 
expression in the adult prefrontal cortex (Roth et al., 2009b). 
Overall, the available data suggest that DNA methylation may indeed be an epigenetic 
mechanism that contributes to the aberrant regulation of genes associated with 
schizophrenia. The hard work to recognize vulnerability genes for multifactorial disorders 
such as schizophrenia, has inspired the development of alternative methodologies. Since 
genetic heterogeneity has been a major dilemma in complex disorders, investigators have 
attempted to increase homogeneity in their samples. Recently, alternative phenotypic 
definitions have been defined that might be more closely linked to biological pathway 
(endophenotypes), for example sensory gating deficits or working memory dysfunction 
(Gottesman and Gould, 2003). 
Another advance to decrease basic genetic complexity is the utilization of genetic isolates. 
Isolated populations originated from a small number of founder couples. Throughout 
history, many populations, counting isolated as well as outbred populations, undergo 
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alternating era of adversities (e.g. war, epidemics, or famine) with period characterized by 
rapid growth of the population. Due to increased inbreeding and genetic drift in isolates, 
certain alleles will be present more frequently in the population, while others are lost, 
increasing genetic homogeneity. Additionally, due to geographic, cultural, or religious 
barriers, isolated populations did not experience a large degree of admixture with adjacent 
peoples for many generations, ensuing in a relatively small gene pool (“founder effect”). 
So the recognition of a gene or allele that clinically and/or genetically is not as important in 
outbred populations as in isolated populations might untangle molecular pathways and 
find out new candidate genes, which might have a higher involvement on illness risk in 
general. Several studies highlight susceptibility loci for schizophrenia in isolated 
populations (Venken et al., 2007). 
4.3 Future research proposals 
The hypothesis that relapse could be predicted by low neurotrophin levels is consistent with 
the neurobiology of relapse and with preliminary data in first episode psychosis patients 
(Parikh et al., 2003). Therefore, large populations of high-risk subjects or untreated first 
episode patients need to be longitudinally investigated to improve the statistical importance 
of the analysis (Pantelis et al., 2003). In fact, in the absence of a neuroleptic naïve cohort 
followed longitudinally to evaluate pattern of neurotrophins over time, it is difficult to 
determine whether any relationship between relapse and low neurotrophins would be due 
to an underlying neurobiological vulnerability to relapse, an inadequate therapeutic 
response to antipsychotics, or inadequate antipsychotic exposure due to medication 
noncompliance. In the first part of the meta-analysis, serum BDNF levels were shown to be 
reduced in patients with schizophrenia even if the difference was moderately significant 
(p<0.05). However, considerable statistical heterogeneity was detected between studies. In 
the second part of the meta-analysis, we found that serum BDNF levels in patients with 
drug free/first episode psychosis were significantly lower in patients compared to healthy 
control subjects, but we could not detect any significant alteration in serum BDNF levels in 
patients with chronic schizophrenia. In both cases, a high heterogeneity was between the 
studies was highlighted and it is still unclear whether the reduction in serum BDNF levels 
observed in drug naïve/first episode patients with schizophrenia is due more to 
antipsychotic treatment or toxic effect of psychosis in itself. Therefore, future biochemical 
studies should longitudinally investigate larger samples of high-risk individuals, drug free 
first-episode patients and unaffected family members. Such populations are crucial to 
systematically examine whether serum BDNF levels changes are already present before the 
appearance of symptoms, or whether they develop afterwards, as a result of the course of 
illness. Such biochemical studies, should be crossed with MRI, genetic and metabolism 
investigations data, in order to further investigate whether serum BDNF levels represent an 
indicator of vulnerability to the disease and to better understand the functional expression 
of serum BDNF levels abnormalities in schizophrenia. 
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